

ISAR HIGHLIGHTS 2025

ISAR ACHIEVEMENTS

We celebrate ISAR's recruitment of **38,527** patients from **31** countries, as well as the achievement of **37** publications and **60** abstracts/posters. ISAR's research has received **1,748 citations** and continues to inform clinical guidelines. We thank all ISAR collaborators for their contributions!



ISAR PUBLICATIONS

There are **eight** ISAR publications so far in 2025, including **SOLAR II** (published in the Blue Journal).

CLEAR

Biologic continuers had fewer exacerbations, lower long-term OCS use and better asthma control than switchers or stoppers at follow-up.

[Full article](#) | [Press release](#) | [Slide deck](#)



ISAR progress update

ISAR's origins, Delphi studies, research, ongoing quality improvement initiatives, and vision for the future are summarized.

[Full article](#)



Biologic choice and timing

There was weak interobserver agreement among asthma specialists in initiating biologics and selecting treatment.

[Full article](#)



Exacerbation prediction

T2 and non-T2 inflammatory pathways predict severe asthma exacerbations.

[Full article](#) | [Press release](#) | [Slide deck](#)



STAR

OCS (intermittent or long-term) use affects BEC distribution and disease burden was high among long-term OCS users irrespective of BEC.


[Full article](#) | [Press release](#) | [Slide deck](#)



SOLAR I

Biologic initiation in patients with severe asthma led to a substantial reduction in total OCS exposure, particularly in the first year.

[Full article](#) | [Press release](#) | [Slide deck](#)



SOLAR II

Biologics prevent new-onset OCS-related adverse outcomes (including diabetes, major cardiovascular events and anxiety/depression) in patients with severe asthma.

[Full article](#) | [Press release](#) | [Slide deck](#)



EMBER

Using a data-driven approach, we identified five distinct T2-biomarker clusters. These were associated with a differential response to biologics.

[Full article](#) | [Press release](#) | [Slide deck](#)



UPCOMING ISAR EVENTS AT REG 2026



ISAR Meetings, 19th March 2026

Venue: Meliá Palma Marina Hotel, Palma de Mallorca, Spain

10:30-11:30 *ISAR Steering Committee meeting* (open to ISC members)

11:45-12:15 *ISAR beyond 2026 meeting* (open to ISC members)

12:30-13:00 *ISAR MOONLIGHT working group meeting* (open to MOONLIGHT working group members)

14:00-15:00 *ISAR QI and ENLIGHTEN working group meeting* (open to ISC and ENLIGHTEN working group members)

15:15-15:45 *ISAR research updates meeting* (open to all ISAR collaborators)

19:00-21:00* *ISAR dinner* (open to all ISAR collaborators)

*Exact timing to be confirmed

ISAR Session, 21st March 2026, 09:00-10:15 CET

Session title: Remission in Severe Asthma - Insights from the International Severe Asthma Registry (ISAR)

- ISAR's practice change goals in severe asthma, including the elimination of long-term OCS use (ENLIGHTEN)
- Impact of earlier access to biologics on remission and natural course of asthma (GLEAM)
- Impact of remission on long-term clinical outcomes of patients with severe asthma (SPOTLIGHT)
- Maintenance of long-term remission and the causes of secondary failure to biologics (SHINE)

ISAR EVENTS (ERS & APSR 2025)



42

collaborators
from

Highlights of the ISAR meetings



- ISAR's **achievements** in patient recruitment, research and publications were highlighted.
- Ideas for the long-term **sustainability of ISAR** were discussed at the ISC meeting and country meetings.
- Project updates were discussed at the working group meetings for **MOONLIGHT**, **SHINE** and **SPOTLIGHT**.
- Ideas for ISAR's QI goal 2026, and **ENLIGHTEN** preliminary analyses on long-term OCS use, were discussed.
- **Practice change tools** such as the OCS risk calculator and RESA (by Dr Wenjia Chen) were shared.

ISAR Industry Symposium

- ISAR held its first symposium with potential industry partners to highlight its research achievements and identify **collaboration opportunities**: real-world datasets, practice change, clinical trial recruitment and education.

ISAR local PRISM posters

- **Canada:** "Novel Insights into the Comorbidity Burden of Severe Asthma in Canada: Analysis of the Canadian Severe Asthma Registry", presented by Dr. Nawaf Alotaibi / [Abstract](#)
- **Mexico:** "Clinical profile of severe asthma (SA) patients Mexican vs Global data and evolution once in the international severe asthma registry (ISAR)", presented by Dr. Désirée Larenas-Linnemann / [Abstract](#)



ISAR PRISM Asia poster, "Corticosteroid burden and potentially related comorbidities in severe asthma: insights from East and Southeast Asia",
was presented by Dr Sachin Joshi (AZ).